A Study of INCMGA00012 in Metastatic Merkel Cell Carcinoma (POD1UM-201)

Official Title

A Phase 2 Study of INCMGA00012 in Participants With Metastatic Merkel Cell Carcinoma (POD1UM-201)


The purpose of this study is to assess the clinical activity and safety of INCMGA00012 in participants with advanced/metastatic Merkel cell carcinoma (MCC).

Trial Description

Primary Outcome:

  • Overall Response Rate (ORR)
Secondary Outcome:
  • Duration of Response (DOR)
  • Disease Control Rate (DCR)
  • Progression Free Survival (PFS)
  • Overall survival (OS)
  • Number of Treatment-Emergent Adverse Events (TEAE)
  • Cmax of INCMGA00012
  • tmax of INCMGA00012
  • Cmin of INCMGA00012
  • AUCt of INCMGA00012

View this trial on ClinicalTrials.gov

Interested in this trial?

Print this page and take it to your doctor to discuss your eligibilty and treatment options. Only your doctor can refer you to a clinical trial.


Canadian Cancer Society

These resources are provided in partnership with the Canadian Cancer Society